<DOC>
	<DOCNO>NCT00789776</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose donor natural killer ( NK ) cell therapy see well work give together fludarabine phosphate , cyclophosphamide , total-body irradiation , donor bone marrow transplant , mycophenolate mofetil , tacrolimus treat patient hematologic cancer . Giving chemotherapy , fludarabine phosphate cyclophosphamide , total-body irradiation donor bone marrow transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Giving infusion donor 's T cell ( donor lymphocyte infusion ) may help patient 's immune system see remain cancer cell belong patient 's body destroy ( call graft-versus-tumor effect ) . Sometimes transplanted cell donor make immune response body 's normal cell . Giving mycophenolate mofetil tacrolimus transplant may stop happening .</brief_summary>
	<brief_title>Fludarabine Phosphate , Cyclophosphamide , Total-Body Irradiation , Donor Bone Marrow Transplant Followed Donor Natural Killer Cell Therapy , Mycophenolate Mofetil , Tacrolimus Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Identification maximal feasible dose NK cell infuse one week nonmyeloablative , human leukocyte antigen ( HLA ) -haploidentical hematopoietic cell transplant ( HCT ) . ( Phase I ) SECONDARY OBJECTIVES : Once maximal feasible dose identify , accrual limit cohort contain cell dose determine : I . Incidence relapse . ( Phase II ) II . Incidence grade III-IV acute graft-versus-host disease ( GVHD ) . ( Phase II ) III . Incidence non-relapse mortality . ( Phase II ) OUTLINE : This phase I , dose-escalation study donor NK cell therapy follow phase II study . CONDITIONING : Patients receive fludarabine intravenously ( IV ) 30 minute day -6 -2 cyclophosphamide IV 1 hour day -6 -5 . Patients undergo total-body irradiation day -1 . DONOR BONE MARROW TRANSPLANTATION : Patients undergo donor bone marrow transplantation day 0 . POST-TRANSPLANTATION IMMUNOSUPPRESSION : Patients receive cyclophosphamide IV 1 hour day 3 mycophenolate mofetil orally ( PO ) thrice daily ( TID ) day 4 40 , follow taper day 84 absence GVHD . Patients also receive tacrolimus IV continuously IV daily ( QD ) 1-2 hour PO twice daily ( BID ) day 4 84 , follow taper day 180 absence GVHD . DONOR NK CELL INFUSION : Patients undergo donor lymphocyte infusion NK cell day 7 . After completion study treatment , patient follow 6 month , 1 year , 1.5 year , every year thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients follow hematologic malignancy permit although diagnosis consider approve Patient Care Conference ( PCC ) principal investigator : Aggressive nonHodgkin lymphoma ( NHL ) histologies diffuse large B cell ( DLBC ) NHL ) eligible autologous HCT , b ) eligible highdose HCT , c ) fail autologous HCT , ) part tandem autoallo approach high risk patient Mantle cell NHL must beyond first complete response ( CR ) Lowgrade NHL &lt; 6 month duration CR course conventional therapy Chronic lymphocytic leukemia ( CLL ) must either 1 ) Failed meet National Cancer Institute ( NCI ) Working Group criteria complete partial response therapy regimen contain FLU ( fludarabine phosphate ) ( another nucleoside analog , e.g . 2chlorodeoxyadenosine [ 2CDA ] , pentostatin ) experience disease relapse within 12 month complete therapy regimen contain FLU ( another nucleoside analog ) 2 ) Failed FLU CY ( cyclophosphamide ) rituximab ( FCR ) combination chemotherapy time point ; 3 ) Have `` 17p deletion '' cytogenetic abnormality relapse time point initial chemotherapy Hodgkin lymphoma must receive ) fail frontline therapy , b ) eligible autologous HCT , c ) part tandem autoallo approach high risk patient Multiple myeloma plasma cell leukemia must receive one line prior chemotherapy ; consolidation chemotherapy autografting prior nonmyeloablative HCT permit Acute myeloid leukemia ( AML ) must &lt; 5 % marrow blast time HCT Acute lymphocytic leukemia ( ALL ) must &lt; 5 % marrow blast time HCT Chronic myeloid leukemia ( CML ) accept beyond chronic phase ( CP ) 1 receive previous myelosuppressive chemotherapy HCT &lt; 5 % marrow blast time transplant Myelodysplasia ( MDS ) /myeloproliferative syndrome ( MPS ) ( &gt; intermediate 1 [ int1 ] per International Prognostic Scoring System [ IPSS ] ) &gt; = 1 prior cycle induction chemotherapy ; must &lt; 5 % marrow blast time transplant Waldenstrom 's macroglobulinemia must fail 2 course therapy Patients must expect disease control least 60 day HCT Patients HLAmatched unrelated donor search could initiate complete due insurance reason , concern rapidly progressive disease , and/or discretion attend physician eligible protocol DONOR : Related , HLAhaploidentical donor identical one HLA haplotype mismatch number HLAA , B , C , DRB1 DQB1 locus unshared haplotype DONOR : Marrow allow hematopoietic stem cell source DONOR : Haploidentical donor selection base standard institutional criterion , otherwise specific prioritization make amongst suitable available donor ; donor select base killer cell immunoglobulinlike receptor ( KIR ) status Patients available HLAmatched related donor Patients eligible curative autologous HCT Significant organ dysfunction would prevent compliance conditioning , GVHD prophylaxis , would severely limit probability survival : 1 ) Symptomatic coronary artery disease ejection fraction &lt; 35 % cardiac failure require therapy ( , unable obtain ejection fraction , shorten fraction &lt; 26 % ) ; shorten fraction &lt; 26 % cardiology consult require principal investigator ( PI ) final approval eligibility 2 ) Diffusion capacity lung carbon monoxide ( DLCO ) &lt; 40 % total lung capacity ( TLC ) &lt; 40 % , forced expiratory volume one second ( FEV1 ) &lt; 40 % and/or receive supplementary continuous oxygen ; Fred Hutchinson Cancer Research Center ( FHCRC ) study PI must approve enrollment patient pulmonary nodule 3 ) Liver function abnormality : patient clinical laboratory evidence liver disease evaluate cause liver disease , clinical severity term liver function , bridge fibrosis , degree portal hypertension ; patient exclude he/she find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease Human immunodeficiency virus ( HIV ) seropositive patient Patients poorly control hypertension despite multiple antihypertensive medication Fertile female unwilling use contraceptive technique twelve month follow treatment , well females pregnant actively breast feed Fertile male unwilling use contraceptive technique twelve month follow treatment Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) nonhematologic malignancy ( except nonmelanoma skin cancer ) render evidence disease , great 20 % chance disease recurrence within five year ; exclusion apply patient nonhematologic malignancy require therapy Active infectious disease concern Karnofsky performance score &lt; 60 Lansky performance score &lt; 60 Life expectancy severely limited disease malignancy Patients diagnosis chronic myelomonocytic leukemia ( CMML ) Central nervous system ( CNS ) involvement disease refractory intrathecal chemotherapy Patients AML , MDS , ALL , CML must presence circulate leukemic blast detect standard pathology Patients aggressive lymphoma ( DLBC ) must bulky , rapidly progressive disease immediately prior HCT Patients receive prior allogeneic HCT must active GVHD require immunosuppressive therapy least 21 day prior start condition DONOR : Children le 12 year age . DONOR : Children great equal 12 year age provide informed assent presence parent attend physician member recipient 's care team DONOR : Children great equal 12 year age inadequate peripheral vein access safely undergo apheresis DONOR : Donors unable unwilling undergo marrow harvest initial HCT , storage autologous blood prior marrow harvest apheresis one week marrow harvest DONOR : Donors expect meet minimum target dose marrow cell ( 1 x 10^8 nucleated cells/kg recipient ideal body weight [ IBW ] ) initial HCT ; average nucleated cell content harvest marrow 22 x 10^6 nucleated cells/mL 220 x 10^8 nucleated cells/Liter DONOR : HIVpositive donor DONOR : Donors crossmatch positive recipient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>